Abstract: The present invention relates to heteroleptic complexes comprising a phenylimidazole or phenyltriazole unit bonded via a carbene bond to a central metal atom, and phenylimidazole ligands attached via a nitrogen-metal bond to the central atom, to OLEDs which comprise such heteroleptic complexes, to light-emitting layers comprising at least one such heteroleptic complex, to a device selected from the group consisting of illuminating elements, stationary visual display units and mobile visual display units comprising such an OLED, to the use of such a heteroleptic complex in OLEDs, for example as emitter, matrix material, charge transport material and/or charge blocker.

Abstract: The present invention provides molecules comprising a modified Fc region which do not mediate antibody effector functions such as antibody-dependent cellular cytotoxicity (ADCC) but maintain a long serum half-life due to binding to the neonetal Fc receptor (FcRn). To this end, the molecules of the present invention do not comprise the disulfide bridges of the antibody hinge region but are linked C-terminally by at least two covalent bonds. Furthermore, the molecules of the present invention comprise CH2 domains with an additional disulfide bond.

Abstract: A vehicle detection system for monitoring stationary and moving vehicles is disclosed. The vehicle detection system includes a housing and a first sensor and a second sensor each configured to detect the moving vehicles. A control unit, and a first energy store as well as a second energy store configured to supply the vehicle detection system with electrical energy independently of one another are also provided. The control unit is designed in such a way that the first sensor is permanently switched on during operation of the vehicle detection system and the second sensor is only switched on for a predetermined time when the first sensor has detected a vehicle. The control unit is designed in such a way that, when the voltage of the first energy store falls below a first predetermined voltage, the vehicle detection system is supplied with electrical energy by the second energy store.

Abstract: Binding proteins comprising a pseudoFab domain including a stabilised knockout domain and a second VH/VL that form a first functional antigen binding domain are provided. Multispecific binding proteins comprising at least one pseudoFab are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.

Abstract: Provided herein are multispecific antibodies, e.g. bispecific antibodies, which are modified such that the desired chain pairing takes place and/or can be selected for. Specifically, this is achieved by using different dimerization domains for light chain pairing. Also disclosed herein are nucleic acids encoding for these antibodies, expression vectors comprising these nucleic acids, cells expressing them, and further to pharmaceutical compositions comprising the antibodies, as well as methods of isolating the antibodies.

Abstract: The present invention relates to protein molecules comprising at least one protease-cleavable linker. It also relates to protein molecules obtainable by protease-cleavage of such protein molecules and their use in therapy.

Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely identifies and maps sensitive information from computers across the enterprise. Secure and sensitive information may be internally encrypted and analyzed for indicators of compromise, threatening behavior, and known vulnerabilities. The remote, agent-less collection, analysis, and identification process can be repeated periodically to detect and map additional sensitive information over time, and may delete itself after completion to avoid detection.

Abstract: Binding proteins comprising a pseudoFab domain including a stabilised knockout domain and a second VH/VL that form a first functional antigen binding domain are provided. Multispecific binding proteins comprising at least one pseudoFab are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.

Abstract: The present invention relates to fusion proteins comprising a Glucagon-Like Peptide-1 Receptor 5 (GLP-1R) agonistic peptide and a variant of human Fibroblast Growth Factor 21 (FGF21). The present invention further relates to the use of fusion proteins comprising a GLP-1R agonistic peptide and a variant of FGF21 as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis in a subject. The present invention also relates to pharmaceutical compositions comprising fusion proteins including a GLP-1R agonistic peptide and a variant of FGF21.

Abstract: The present invention relates to Glucagon-Like Peptide-1 Receptor (GLP-1R) agonistic peptides with reduced GLP-1R CA agonistic activity, and fusion molecules comprising the same. The present invention also relates to nucleic acid molecules encoding GLP-1R agonistic peptides with reduced GLP-1R agonistic activity, pharmaceutical compositions and combinations comprising GLP-1R agonistic peptides with reduced GLP-1R agonistic activity, and kits including GLP-1R agonistic peptides with reduced GLP-1R agonistic activity. The present invention further relates to the use of GLP-1R agonistic peptides with reduced GLP-1R agonistic activity as medicaments, in particular, for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopa-CA thy, hyperglycemia, dyslipidemia, NASH and/or atherosclerosis.

Abstract: The invention relates to a protein complex comprising at least two polypeptide chains A (PCA) and B (PCB), wherein PCA comprises a heterodimerization domain A (HDA) and PCB comprises a heterodimerization domain B (HDB), wherein HDA and HDB bind to each other and wherein one heterodimerization domain comprises or consists of two N-terminal ?-strands (N-?) of an immunoglobulin (Ig) domain and the other heterodimerization domain comprises or consists of two C-terminal ?-strands (C-?) of an Ig domain. The invention further relates to polynucleotides encoding one or more polypeptides of the protein complex, expression vectors comprising the polynucleotides and a cell comprising the polynucleotides or the expression vectors.

Abstract: The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.

Abstract: The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.

Abstract: The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.

Abstract: Provided herein are FGFR1/KLB targeting agonistic antigen-binding proteins, or fragments thereof, having improved physico-chemical properties. Also provided herein are conjugates comprising an FGFR1/KLB targeting agonistic antigen-binding protein, or a fragment thereof, and at least one GLP-1R agonistic peptide. Further provided are pharmaceutical compositions comprising the antibody (or fragment thereof), or the conjugate provided herein, and the use of the antibody (or fragment thereof, or the use of the conjugate in medicine.

Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely identifies and maps sensitive information from computers across the enterprise. Secure and sensitive information may be internally encrypted and analyzed for indicators of compromise, threatening behavior, and known vulnerabilities. The remote, agent-less collection, analysis, and identification process can be repeated periodically to detect and map additional sensitive information over time, and may delete itself after completion to avoid detection.

Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely identifies and maps sensitive information from computers across the enterprise. Secure and sensitive information may be internally encrypted and analyzed for indicators of compromise, threatening behavior, and known vulnerabilities. The remote, agent-less collection, analysis, and identification process can be repeated periodically to detect and map additional sensitive information over time, and may delete itself after completion to avoid detection.

Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely collects system information from computers across the enterprise, internally encrypts and analyzes the collected information for indicators of compromise, threatening behavior, and known vulnerabilities, and generates alerts regarding known and potential threats for further analysis and remediation. If potential threats are identified, the system may deploy a memory analysis module that takes a deeper analysis of the potentially compromised computer to obtain more information about the potential threat.

Abstract: The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.

Abstract: Binding proteins comprising a pseudoFab domain including a stabilised knockout domain and a second VH/VL that form a first functional antigen binding domain are provided. Multispecific binding proteins comprising at least one pseudoFab are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.